Royalty Report: Medical, Device, Delivery – Collection: 378

License Grant

The Company has exclusive right to manufacture, market and distribute products utilizing automated retraction technology.

License Property

VanishPoint(R) products invented by 80% shareholder are designed specifically to prevent needlestick injuries and to prevent reuse.  The friction ring mechanism permits the automated retraction of the syringe needle into the barrel of the syringe, directly from the patient, after delivery of the medication is completed.

U.S. Patent 5,120,310, Issued June 9, 1992, entitled Nonreusable Syringe; U.S. Patent 5,188,613, Issued February 23, 1993, entitled Nonreusable Syringe with Safety Clip; U.S. Patent 5,267,961, Issued December 7, 1993, entitled Nonreusable Syringe with Safety Clip; Foreign Counterpart Patent Applications on the Nonreusable Syringe with Safety Clip corresponding to U.S. Patents 5,120,310 and 5,188,613 for Europe (Serial No. 92910361.2), China (Serial No. 92102245.X), India (Serial No. 186/CAL/92), Mexico (Serial No. 92-01493), and Taiwan (Serial No.  82205282); U.S. Patent 5,423,758, Issued June 13, 1995, Entitled Retractable Fluid Collection Device and a Counterpart Patent Cooperation Treaty Application Serial No. 94/13953, Entitled Blood Sampler, Filed December 6, 1994 designating all PCT countries; U.S. Patent 5,385,551, Issued January 31, 1995, Entitled Nonreusable Syringe with Front Retraction and a Counterpart Patent Cooperation Treaty Application Serial No.  PCT/US94/10235, Filed September 7, 1994 designating all PCT countries; U.S. Patent 5,389,076, Issued February 14, 1995, Entitled Single Use Medical Device with Retraction Mechanism and a Counterpart Patent Cooperation Treaty Application Serial No.  PCT/US95/03953, Filed March 31, 1995 designating all PCT countries; U.S. Patent Application Serial No. 380107, Filed January 30, 1995, Entitled Syringe Plunger Seal and Locking Assembly, and the right to file Patent Applications thereon in nearly any foreign country until January 30, 1996; and A new U.S. Patent Application filed in May, 1995, Entitled Tamperproof Retractable Syringe with Serial No. 08/438,954, and the right to file Patent Applications thereon in nearly any foreign country until May, 1996.

Field of Use

The field of use shall mean the syringe technology relating to the healthcare industry.

License Grant

The Company entered into an Exclusive Patent License Agreement with an Individual whereby the Company obtained an exclusive worldwide license to perfect, produce and market a disposable syringe with needle retraction ('Safety Syringe') and practice the U.S. Patent No. 5,125,898 ('Patent').

License Property

The safety syringe design is a single-handed, vacuum-operated syringe that retracts the needle into the barrel of the syringe after use.  The vacuum is created at the time of manufacture.  The safety syringe is a disposable retractable syringe that uses a proprietary, patented technology whereby a vacuum causes the needle to retract into the barrel of the syringe after an injection is administered.  The safety syringe is intended to be a cost-effective alternative to traditional disposable syringes and is intended to avoid the danger of accidental needle puncture associated with traditional disposable syringes.

License Grant

Licensor agrees to grant, deliver and convey to Licensee and hereby does grant, deliver and convey to Licensee an exclusive license to and under the Patent Rights to manufacture, produce, use, market, promote, transport, distribute and sell Retractable Syringes containing improvements covered by the Patent Rights throughout the Geographic Territories.

License Property

Licensor is the owner by assignment and otherwise of all right, title and interest in and to those certain patent rights (defined below) covering improvements in disposable retractable hypodermic syringes.  Retractable Syringe(s) shall mean a disposable hypodermic medical syringe which contains a retractable hypodermic needle and is the subject of the patent rights defined below.  United States Patent No's. (a) 4,790,822; (b) 4,950,251; (c) 5,152,750; (d) 5,342,323; (e) 5,453,093.

In view of the above considerations there is provided a disposable hypodermic syringe with a needle carried by a needle carrier that is retractable into the barrel after use for anti-pricking protection. Additionally, the hypodermic syringe plunger is locked to the needle carrier to prevent any further use of the syringe. After the needle carrier and needle are locked into the retractable position, the plunger may be broken-off even with the barrel so that the needle may not be accidentally pushed out of the barrel and become exposed again.

Field of Use

The rights granted apply to hypodermic needles.

License Grant

The Company entered into an Exclusive License Agreement, pursuant to which the Company acquired the exclusive worldwide license to manufacture and market a new proprietary safety syringe invented and being developed by the Licensor (the Ripp Syringe).

License Property

This new syringe is a single-handed, vacuum-operated safety syringe that retracts the needle into the barrel of the syringe after use.  The vacuum is created at the time of use, not at the time of manufacture.

Field of Use

The rights granted apply to a vacuum-operated syringe.

License Grant

Licensor hereby grant an exclusive, worldwide, right and license, with the right to grant sublicenses as hereinafter set forth, to use the Technology Rights and the Technology, which such license permits SGPF to construct, hire others to construct, use, promote, market, offer for sale and sell the Product and the Technology.

License Property

Product includes a Safety Syringe System, with and without a Distal Protective Needle, in a Fillable and Pre-filled Configuration.

Licensor owns the entire right, title and interest in the following Patents and Patent Applications and in the inventions described and claimed therein
i. U.S. Patent Number 7,198,617 B2, issued on April 3, 2007, entitled 'Passively Guarded, Fillable Injection Syringe'.
ii. U.S. Patent Application No. 11055415, filed February 10, 2005, entitled 'Syringe Guard with Selected Needle Configurations';
iii. U.S. Patent Application No. 11140583, filed May 27, 2005, entitled 'Passively Guarded, Pre-filled Injection Syringe' (ClP);
iv. Syringe Guard tor Pre-filled medicament vial, US application number 11/211,336 filed on August 25, 2005;
v. Hypodermic Needle Tip Protector, Application number 11/422,851 filed on June 7, 2006;
vi. PCT Application No. US2005/018178, entitled 'Passively Guarded, Fillable Injection Syringe';
vii. PCT Application No. US2006/004286, entitled 'Syringe Guard with Selected Needle Configurations';
viii. PCT Application No. US2006/004068, entitled 'Passively Guarded, Prefilled Injection Syringe'; and
ix. To be filed PCT for 'Hypodermic Needle tip Protector'

License Grant

Licensor hereby grants to Licensee (i) an exclusive worldwide right and license, under the Patent Rights to make, have made, use and sell the Licensed Products, together with the right to grant sublicenses throughout the world; (ii) an exclusive worldwide right and license to use the Technical Information to make or have made the Licensed Products, together with the right to grant sublicenses throughout the world; to make, have made, use and sell said certain inventions relating to retractable needle assemblies.

License Property

Technology refers to certain inventions relating to retractable needle assemblies, including, including, but not limited to the Safe Step Safety Blood Collection Needle, Safe Step Safety Winged Set Blood Collection Needle, Safe Step Safety Wing Needle Set/Catheter, Safe Step Safety PICC Catheter System and Safe Step Safety I.V. Catheter Systems (U.S. Patent No. 4,900,307).

License Grant

We started to collaborate with the Company in 2003 for the development of the Unifill syringe as a next-generation drug delivery safety device. We have signed an exclusive licensing Agreement with the Company. Under the exclusive licensing Agreement, we have granted the Company an exclusive License to certain of our intellectual property in order and solely to develop, in collaboration with us, the Unifill syringe for use in and sale to the prefilled syringe market within those therapeutic areas to be agreed upon between us, and a non-exclusive License outside those therapeutic areas that are exclusive to the Company or after the expiration of the exclusive License with the Company. Under the exclusive licensing Agreement, we are not precluded from using certain of our intellectual property to develop, License and sell any products in any market other than the ready-to-fill syringe market, or from entering into licensing or other business arrangements with other pharmaceutical companies for the ready-to-fill syringe market outside those therapeutic areas that are exclusive to the Company, or after the expiration of the exclusive License with the Company.

License Property

We are a U.S. based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for our products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities, and patients who self-administer prescription medication. All of our syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and injury from other unsafe injection practices. Our main product is the Unifill ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with their injectable drugs and vaccines.

Field of Use

The Company is a large, global pharmaceutical company, whose products span multiple therapeutic areas, including cardiovascular diseases, thrombosis, oncology, metabolic diseases, internal medicine and vaccines. We believe that sanofi-aventis is currently the world’s largest purchaser of prefilled syringes.

License Grant

Sellers, Director of Clinical Affairs of the Licensee, by this instrument do hereby sell, transfer and assign to Milestone, all of their rights in and to the “Intellectual Property'.

License Property

The technology is for underlying the SafetyWand, CompuFlo technology and an improvement to the controls for CompuDent.

The SafetyWand is the first, patented safety-engineered injection device that conforms to standards while also meeting the clinical needs of dental and medical practitioners. SafetyWand disposable handpiece, a patented injection device that incorporates safety engineering sharps protection features to aid in the prevention of needlesticks. The SafetyWand is the first patented injection device to be fully compliant with OSHA regulations under the federal Needlestick Safety Act while meeting the clinical needs of dentists.

The CompuFlo technology is a computer-controlled, pressure sensitive infusion, perfusion, and aspiration technology capable of delivering critically important information, in visual and audible forms, that allows physicians, dentists and other health care specialists to determine the characteristics of human and other tissue into which fluids are being delivered (or extracted).

The Sellers have developed the technology, know-how and other intellectual property underlying their invention of (I) a “Pressure/Force Computer Controlled Drug Delivery System”, (ii) a “Universal Syringe Holder Enhancement” (iii) a non-deflecting, non-clogging single use disposable hypodermic needle, (iv) a Handpiece for Injection Device with a retractable rotating needle (US Patent No. 6,428,517 B1), Anti-deflection/force penetration reduction rotating syringe (US Patent No. 6,428,517), for use as a separate drug delivery or aspiration system or as an adjunct to Milestone’s computer controlled anesthesia system known as “The CompuDent/CompuMed/WandTM, (v) a Local Anesthetic and Delivery Injection Unit with Automated Rate Control (US Patent No. 6,652,482 B2), (vi) Safety IV Catheter Infusion Device (US Utility Patent App 10/174,246) (vii) Drug Delivery System with Profiles (notice of allowance issued) and Pressure/Force Computer Controlled Drug Delivery with automated changing (notice of allowance issued) (viii) any and all other patent submissions, past, present and future, that bear the name of one or both of the Sellers (collectively, the Intellectual Property).

Field of Use

The products currently that have embodied these Proprietary rights are the SafetyWandTM, The CompuMed/Wand-PDL Drive Unit device, a.k.a. The CompuDent Single Tooth Anesthesia Drive Unit device, The CompuFloTM.  device, and the SuperSafe – safety engineered dental syringe device.

CompuDent provides painless injections for all routine dental treatments including root canals, crowns, fillings and cleanings.

License Grant

HOSPITAL hereby grants to COMPANY in the LICENSE FIELD in the LICENSE TERRITORY for the LICENSE TERM
  (i) an exclusive, royalty-bearing license under PATENT RIGHTS to make, have made, use, have used, sell, offer to sell, have sold, and TRANSFER PRODUCTS and to use, have used, otherwise practice and have practiced and TRANSFER PROCESSES;

  (ii) the nonexclusive right to disclose, use and transfer TECHNOLOGICAL INFORMATION disclosed by HOSPITAL to COMPANY hereunder; and

  (iii) the right to grant sublicenses under the rights granted.

License Property

This product has achieved FDA clearance, to market CoolSculpting, for the selective reduction of fat.

The Licensee is a medical technology company focused on developing and commercializing products utilizing the proprietary controlled-cooling technology platform.

The first commercial product, the CoolSculpting System, selectively reduces stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.

CoolSculpting utilizes precisely controlled cooling to reduce the temperature of fat cells in the treated area, which leads to fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. Our clinical studies demonstrate that a single CoolSculpting procedure safely, noticeably, and measurably reduces the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

PATENT RIGHTS  1. US Utility Patent Application, Serial
No. 10/391,221, filed on March 17th, 2003,
claiming priority from US Provisional Application, Serial No. 60/365,662, filed on March 15th, 2003.  2. US Utility Patent Application, Serial No. 11/016,196, filed
on December 17th, 2003, a continuation in part of US
Utility Patent Application, Serial No 10/391,221.  3. PCT Patent Application, Serial No. US03/08014, filed on March 17, 2003.
4. Australia Patent Application No. 2003220311, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003.
5. Brazil Patent Application No. 0308642.9, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003.
6. Canada Patent Application No. 2,478,887, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003.
7. China Patent Application No. 03810938.7, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003.
8. Israel Patent Application No. 164115, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003.
9. Japan Patent Application No. 2003-576590, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003.
10. Mexico Patent Application No. 2004-008992, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003.
11. EPO Patent Application No. 03711609.7, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003.

Field of Use

License Field shall mean removal of cutaneous, subcutaneous or subdermal fat, treatment or removal of cellulite, andany therapy or procedures (including without limitation aesthetic therapies or procedures) to the tissues and structures of the skin (including without limitation sweat glands and hair follicles), subcutaneous tissue, and tumors, lesions and adipose tissue of the skin and of subdermal tissue

The Licensee shall itself or through an Affiliate or sublicensee make a first commercial sale within the following countries and regions within the following number years after the effective date of the Agreement
United States of America – Six years
Japan – Seven years
Latin America – Seven years
EPO – Seven years

License Grant

The Company has licensed the rights to a locking device patent to develop a 3cc locking syringe which are designed to make accidental or deliberate reuse difficult.  The Licensor is undisclosed.

License Grant

The Licensor and the Canadian Licensee entered into an exclusive license agreement for certain patent 6,464,670 rights and technology relating, among other things, to suppositories for use in the genitourinary or gastrointestinal system.

Field of Use

Field shall mean the use of suppositories in the genitourinary or gastrointestinal system.

License Grant

The Companys Interim Chief Executive Officer sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with the Director of Clinical Affairs of the Company.

In the original Technology Sale Agreement, the third party, who is the other co-inventor, agreed to a certain royalty amount based on net sales of various licensed products.

This amendment allows the Company to reduce royalties paid on dental products to the third party and in place to pay those royalties to the Companys Interim Chief Executive Officer in exchange for his assignment of his rights to the technology.

License Property

The technology is for underlying the SafetyWand, CompuFlo technology and an improvement to the controls for CompuDent.

The SafetyWand is the first, patented safety-engineered injection device that conforms to standards while also meeting the clinical needs of dental and medical practitioners. SafetyWand disposable handpiece, a patented injection device that incorporates safety engineering sharps protection features to aid in the prevention of needlesticks. The SafetyWand is the first patented injection device to be fully compliant with OSHA regulations under the federal Needlestick Safety Act while meeting the clinical needs of dentists.

The CompuFlo technology is a computer-controlled, pressure sensitive infusion, perfusion, and aspiration technology capable of delivering critically important information, in visual and audible forms, that allows physicians, dentists and other health care specialists to determine the characteristics of human and other tissue into which fluids are being delivered (or extracted).

The Sellers have developed the technology, know-how and other intellectual property underlying their invention of (I) a “Pressure/Force Computer Controlled Drug Delivery System”, (ii) a “Universal Syringe Holder Enhancement” (iii) a non-deflecting, non-clogging single use disposable hypodermic needle, (iv) a Handpiece for Injection Device with a retractable rotating needle (US Patent No. 6,428,517 B1), Anti-deflection/force penetration reduction rotating syringe (US Patent No. 6,428,517), for use as a separate drug delivery or aspiration system or as an adjunct to Milestone’s computer controlled anesthesia system known as “The CompuDent/CompuMed/WandTM, (v) a Local Anesthetic and Delivery Injection Unit with Automated Rate Control (US Patent No. 6,652,482 B2), (vi) Safety IV Catheter Infusion Device (US Utility Patent App 10/174,246) (vii) Drug Delivery System with Profiles (notice of allowance issued) and Pressure/Force Computer Controlled Drug Delivery with automated changing (notice of allowance issued) (viii) any and all other patent submissions, past, present and future, that bear the name of one or both of the Sellers (collectively, the Intellectual Property).

Field of Use

The products currently that have embodied these Proprietary rights are the SafetyWandTM, The CompuMed/Wand-PDL Drive Unit device, a.k.a. The CompuDent Single Tooth Anesthesia Drive Unit device, The CompuFloTM.  device, and the SuperSafe – safety engineered dental syringe device.

CompuDent provides painless injections for all routine dental treatments including root canals, crowns, fillings and cleanings.

License Grant

The Licensor hereby grants to Licensee the Exclusive and sublicensable right in the Field in the Territory, under the Patent Rights and Medi-Ject Know How and Improvements only for the Field, to use, have used, sell and have sold, but not manufacture, the Device(s) in the Territory for the Term of this Agreement.

License Property

The Licensor owns valuable Medi-Ject Know How (hereinafter defined) and has been granted patent protection relating to the disposable front-end chamber and adaptor for such needle-free injector devices and Licensor is desirous of developing, Exclusively licensing and supplying such devices in the Territory to Licensee for use in the treatment of human growth disorders and further indications in the Field.  The Licensor has acquired the rights to an improved Device(s) which is a needle-free injector device system capable of delivering drugs through the skin in a controlled manner.

'Disposable Front End Chamber(s)' means a system which is filled with medicant at the time of administration and used to hold and administer the medicant needle-free.

Device(s) means those Medi-Ject needle-free injector devices.

The MJ7 is a needle-free drug delivery system composed of a power pack, a needle-free syringe assembly, an adapter assembly for drawing drug from a traditional glass vial and an adapter cap to serve as a container closure for the drug vial. The power pack is reusable and is connected with the needle-free syringe when injecting or aspirating drug. The device is hand-held and spring powered. The delivered dose can be varied by the user up to the maximum of 0.5 ml in 0.01 ml increments. The needle-free syringe, adapter assembly and adapter cap are the only drug or injection site contacting materials, and these parts and assemblies are provided to the end user as sterile. The device is readied for use, or armed, by manually compressing a spring using a rotating or twisting motion. A similar but opposite twisting motion is used to dose the needle-free syringe when it is attached to the power pack. The drug to be delivered is injected by holding the device against the injection site with slight pressure and in a fashion that the needle-free syringe is in intimate contact with the injection site. Pushing a button which releases the energy stored in the spring triggers the injection. This device includes a safety mechanism that prevents inadvertent firing of the device. The safety is automatically set in the safe or non-firing mode when the device is armed. The safety prevents device actuation by preventing the button from being pushed. The device is primarily cylindrical in shape with a maximum diameter of approximately 1-inch. The length of the device is approximately 6 inches when the spring is fully compressed and the needle-free syringe is not attached. The device is approximately 7 3/4 inches when the device is fully extended at a dosage setting of 0.5 ml and the needle-free syringe is attached. The weight of the device is approximately 1/3 lbs. (135 grams) without the disposable components.

APPENDIX B – PATENTS

U. S. PATENTS – ISSUED

4,507,113               HYPODERMIC JET INJECTOR
Des.304,616           MEDICAMENT INJECTOR
5,062,830               DRY DISPOSABLE NOZZLE ASSEMBLY FOR MEDICAL JET INJECTOR
5,697,917               NOZZLE ASSEMBLY WITH ADJUSTABLE PLUNGER TRAVEL GAP
5,722,953               NOZZLE ASSEMBLY FOR INJECTION DEVICE
5,769,138               NOZZLE AND ADAPTER FOR LOADING MEDICAMENT INTO AN INJECTOR            
5,800,388               PLUNGER/RAM ASSEMBLY ADAPTED FOR A FLUID INJECTOR

5,836,911               INJECTION DEVICE HAVING POSITIONING
5,846,233               COUPLING DEVICE FOR MEDICAL INJECTION SYSTEM
5,865,795               SAFETY MECHANISM FOR INJECTION DEVICES
5,891,085               NOZZLE ASSEMBLY WITH LOST MOTION CONNECTION FOR MEDICAL                                                     INJECTOR ASSEMBLY
5,921,967               PLUNGER FOR NOZZLE ASSEMBLY
5,875,976               LOCKING MECHANISM FOR NOZZLE ASSEMBLY

APPLICATIONS – FILED

60/094,163             LOADING MECHANISM FOR MEDICAL INJECTOR ASSEMBLY
60/094,167             INJECTION-ASSISTING PROBE FOR MEDICAL INJECTOR

Field of Use

Field means using hGH to treat any human ailment.

License Grant

Hospital hereby grants to Company the following

(i) an exclusive, royalty-bearing license under patent rights to make, have made, use, have used, sell, offer to sell, have sold, and Transfer Products and to use, have used, otherwise practice and have practiced and Transfer Processes;

(ii) the nonexclusive right to disclose, use and Transfer Technology IinformationTechnological Information disclosed by Hospital to Company hereunder; and

(iii) the right to grant sublicenses under the rights granted in Section 2.l(a)(i) and 2.1(a)(ii) to Sublicensees, provided that in each case Compny shall be responsible for the performance of any obligations of Sublicensees relevant to this Agreement as if such performance were carded out by Company itself, including, without limitation, the payment of any royalties or other payments provided for hereunder, regardless of whether the terms of any sublicense provide for such amounts to be paid by the Sublicensee directly to Hospital.

License Property

This product has achieved FDA clearance, to market CoolSculpting, for the selective reduction of fat.

The Licensee is a medical technology company focused on developing and commercializing products utilizing our proprietary controlled-cooling technology platform.

Our first commercial product, the CoolSculpting System, selectively reduces stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.

CoolSculpting utilizes precisely controlled cooling to reduce the temperature of fat cells in the treated area, which leads to fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. Our clinical studies demonstrate that a single CoolSculpting procedure safely, noticeably, and measurably reduces the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

PATENT RIGHTS
1. US Utility Patent Application, Serial No- 10/391,221, filed on March 17th, 2003, claiming priority From US Provisional Application, Serial No. 60/365,662, filed on March 15th, 2003.
2. US Utility Patent Application, Serial No. 11/016,196, filed on December 17th, 2003, a continuation in part of US Utility Patent Application, Serial No 10/391,221.
3. PCT Patent Application, Serial No. US03/08014, filed on March 17, 2003.
4. Australia Patent Application No 2003220311, claiming priority from PCT Patent Application No. PCT/US03/08014, tiled on March 17th, 2003.
5. Brazil Patent Application No, 0308642.9, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on March 17th, 2003.
6. Canada Patent Application No. 2,478,887, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on March 17th, 2003.
7. China Patent Application No, 03810938.7, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on March 17th, 2003.
8. Israel Patent Application No. 164115, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on March 17th, 2003.
9. Japan Patent Application No. 2003-576590, claiming priority from PCT Patent Application No PCT/US03/08014, filed on March 17th, 2003.
10. Mexico Patent Application No. 2004-008992, claiming priority from PCT Patent Application No PCT/US03/08014, filed on March 17th, 2003.
11. EPO Patent Application No. 03711609.7, claiming priority from PCT Patent Application No, PCT/US03/08014, filed on March 17th, 2003.

Field of Use

“LICENSE FIELD” shall mean removal of cutaneous, subcutaneous or subdermal fat, treatment or removal of cellulite, and any therapy or procedures (including without limitation aesthetic therapies or procedures) to the tissues and structures of the skin (including without limitation sweat glands and hair follicles), subcutaneous tissue, and tumors, lesions and adipose tissue of the skin and of subdermal tissue.bb

License Grant

The Licensors, two individuals, assigned all of their rights, title and interest throughout the world in, to and under certain improvements relating to blood analyzers and disposable syringes for use in medical analyzers in U.S. Patent No. 5,066,859, U.S. Patent Application Serial No. 07/789,088 and a Patent and Cooperation Treaty Patent Application entitled 'Hematocrit and Oxygen Saturation Blood Analyzer'.

License Property

U.S. Patent No. 5,066,859, 'Hematocrit and Oxygen Saturation Blood Analyzer'

License Grant

The Company entered into an agreement to acquire the patents, patent applications and related rights to the technology underlying the Vacuette® Premium Winged Safety Blood Collection Set.

License Property

Our Vacuette® Premium Winged Safety Blood Collection Set is used for infusion and blood collection. It is a single use, sterile device designed with a fully passive safety system that engages upon completion of access when the user grips the wings and pushes them up. When the wings close to approximately 20 degrees, the safety guard automatically releases over the needle.  The user then removes the device from the patient’s skin with the needle fully covered by the guard.  The guard secures itself over the needle into a fully extended and locked position covering the needle, preventing the wings from reopening, and preventing any exposure of the contaminated sharp to the user.  The user then discards the device without ever having actively deployed the guard or touched the needle.  We received FDA 510(k) clearance for the winged blood collection set during the fourth quarter of 2010.

Field of Use

The Field of Use apply to the medical industry relating to blood.

License Grant

University is willing to grant a worldwide, exclusive license in the defined FIELD OF USE to Licensee.  The University is the owner and that it has the right to exclusively license those inventions which are the subject matter of USC File No. 2651 entitled 'Balloon Protection Guide Wire Device For Carotid Balloon Angioplasty and Stenting' and USC Pile 2639 entitled 'New Balloon-Inflated Carotid Artery Stent to Assist in Carotid Artery Balloon Angioplasty'.

License Property

Guardian Embolization Protection System patented technology with primary use in the neurointerventional and cardiology markets these markets focus on arteries and veins leading to the brain and those in the heart, and the removal of blockages in these veins and arteries.  The device is designed to prevent deadly embolisms during surgery to clear blocked arteries and prevent strokes and heart attacks.  The key to this device, known as the Guardian System, is a thin string of wire, really a metal tube not much larger in diameter than a human hair, with a marble-sized balloon attached toward the end.

USC File 2651 U.S. Patent Application Serial No. 08/767,221 filed December 16, 1996 (abandoned) entitled 'Cerebral Protection Balloon For Use In Carotid Artery Angioplasty and Stenting'

USC File 2561 U.S. Patent Application Serial No. 08/906,890 filed August 6,1997 (which is a continuation of U.S. Ser. No. 08/767,221), entitled Angioplasty Catheter'.

USC File 2561 PCT Patent Application Serial No. PCT/US97/23257 filed December16, 1997 and corresponding to U.S. Patent Applications Serial Nos. 08/767,221and 08/906,890.

USC File 2639 Invention Disclosure entitled 'New Balloon-Inflated Carotid Artery Stent to Assist in Carotid Artery Balloon Angioplasty'.

Field of Use

'FIELD OF USE' shall mean diagnostic and/or therapeutic devices to be used in the treatment or management of patients via the carotid artery or other arteries or veins.

License Grant

Inventors, two of whom are former officers and directors of the Licensee hereby grant and Licensees hereby accept exclusive licenses for the entire world to make, use and sell Products. Such licenses are perpetual, subject to the payment of royalties as provided herein.

License Property

'Gel Patents' shall refer to United States Patent No. 5,067,965, Bio-Oncotic Gel for Implant Protheses
'Micro Implant Patents and Patent Applications' refers to United States patent Application Serial Number 07/232,671, an Application, allowed in part and issued on November 2, l993, as Patent No. 5,258,028, United States Patent for Textured Micro Implants

'Reflux Disorders Patent Application' refers to United States Patent Application Serial Number 07/863,848, entitled Treatment of Urologic and Gastric Fluid Reflux Disorders by Injection of Micro Particles

Field of Use

Multiple patents Macroplastique(r) Implants are an injectable medical device implant designed to treat certain forms of urinary / in a minimally invasive procedure involving injection of the product material through a needle into the soft tissue at the bladder neck to act as a tissue bulking agent.

License Grant

Licensor hereby grants to Licensee and its Affiliates a non-exclusive license, with the right to sublicense upon written approval of Licensor, which approval shall not be unreasonably withheld, under the Patents for the Technology to make, have made, develop, have developed, use offer to sell, sell, lease, transfer, import or otherwise dispose of the Products within the Field of Use in the Territory for the Term under the terms and conditions set forth herein.

License Property

Patents shall mean all patent applications filed in any country claiming benefit of the filing date of any of the patents, or applications and listed in hereunder, including all continuation, continuation-in-part, divisional, and renewal applications thereof, all patent applications and patents granted thereon, and all reissues, re-examinations and extensions thereof to the extent that they contain, or are amended to contain, a claim covering the Technology.

6,595,955 – Safety shield for medical needles
6,902,546 – Safety shield for medical needles

Technology shall mean a positioning member integral with a binding member having one or more binding surfaces, wherein the positioning member pushes against a needle and the binding member inclines by pushing of the positioning member when a portion of the retainer in contact with the needle is advanced past a distal end of the needle, as disclosed in the Patents. An example of the Technology is a leaf spring integral to the binding member for positioning the binding surfaces to secure a shield to the needle. Technology specifically excludes various embodiments of friction elements to cause inclination of a binding member into a binding position on a needle as disclosed in the Patents.

Products shall mean peripheral IV catheter products having the Technology that are covered by any Valid Claim of an issued or granted patent included in Patents, for each country in which such products are made, used or sold. Products shall mean only those component products of a collection of products that Licensee may manufacture, assemble and/or sell as a packaged product that, but for the license granted hereunder, infringe any Valid Claim of an issued or granted patent for the Technology. For example, if Licensee should manufacture and sell a peripheral safety IV catheter Product as part of a larger surgical kit, including other products, which themselves are not Products under this Agreement, the surgical kit would not be a Product, only the component peripheral safety IV catheter would be a Product. Further, any additional component, such as a catheter valve, that is not covered by the Patents, would not be a Product. Moreover, Products specifically excludes peripheral safety IV catheter devices utilizing various embodiments of friction elements to cause inclination of a binding member into a binding position on a needle as disclosed in the Patents.

Field of Use

Field of Use shall mean medical or veterinary applications related to any peripheral safety IV catheter connected to or placed in a patient’s body.